---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-001495"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:42:30.375855+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics appoints Sung H. Lee to Board; grants option for 60k shares at $8.93

## Summary
- Board expanded to 8; Lee appointed as Class I director, term until 2028 annual meeting.
- Lee to receive stock option for 60,000 shares at $8.93, vesting monthly over 3 years.
- Lee to receive RSU for 10,000 shares vesting annually over 3 years; $40k annual retainer.
- Lee is EVP & CFO at Cytokinetics, previously CFO at Vir, MorphoSys, Sangamo; 20+ yrs finance experience.
- CEO says Lee's expertise will support lead program vopimetostat in registrational studies.

## SEC filing metadata
- accession: 0001193125-26-001495
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312526001495/0001193125-26-001495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312526001495/d44532d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-001495
- JSON: https://secwatch.observer/filing/0001193125-26-001495.json
- Plain text: https://secwatch.observer/filing/0001193125-26-001495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.